From: Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center
Disease subtype (n of patients) | Diffuse SSc (n = 2) | Limited SSc (n = 9) | Sine SSc (n = 10) |
---|---|---|---|
Maternal age at delivery (y) | 38.8 ± 1.15 | 34.3 ± 4.69 | 36.0 ± 3.23 |
Disease duration at conception (y) | 12 ± 10.4 | 6.4 ± 5.2 | 4.45 ± 5.7 |
Cumulative clinical manifestations | |||
Raynaud’s phenomenon | 2 (100) | 9 (100) | 10 (100) |
Digital ulcers | 2 (100) | 3 (33.3) | 1 (10) |
Arthritis | 1 (50) | 2 (22.2) | 0 |
Telangiectasia | 2 (100) | 4 (44.4) | 0 |
Calcinosis | 1 (50) | 2 (22.2) | 0 |
Puffy fingers/sclerodactyly | 2 (100) | 6 (66.7) | 0 |
Esophageal dysmotility | 2 (100) | 4 (44.4) | 3 (30) |
Interstitial lung disease | 2 (100) | 4 (44.4) | 1 (10) |
FVC (%) | 80 ± 21.7 | 84.6 ± 16.9 | 99.3 ± 8.4 |
DLCO (%) | 68.3 ± 21.3 | 69.6 ± 22 | 78.3 ± 11.9 |
Pulmonary arterial hypertension | 0 | 0 | 0 |
Scleroderma renal crisis | 0 | 0 | 0 |
Immunological features | |||
Antinuclear antibodies | 2 (100) | 9 (100) | 10 (100) |
Anti-Scl70 antibody | 1 (50) | 2 (22.2) | 1 (10) |
Anti-centromere antibody | 0 | 2 (22.2) | 6 (60) |
Anti-RNA polymerase antibody | 1 (50) | 2 (22.2) | 1 (10) |
Anti-cardiolipin antibodies | 0 | 0 | 0 |
Anti-β2GPI antibodies | 0 | 1 (11.1) | 0 |
Lupus anticoagulant | 0 | 0 | 0 |
Anti-Ro/SSA antibody | 0 | 3 (33.3) | 2 (0) |
Treatment at conception | |||
Calcium channel blockers | 0 | 4 (44.4) | 3 (33.3) |
ERA | 0 | 1 (11.1) | 1 (10) |
PDA-5 inhibitors | 0 | 0 | 0 |
Proton pump inhibitors | 1 (50) | 1 (11.1) | 2 (20) |
Corticosteroids | 1 (50) | 3 (33.3) | 1 (10) |